Revolution Medicines
RVMD
161.20
+1.77
+1.11%
Revolution Medicines
US · RVMD
#499 by market cap
Listed 2020
161.20
+1.77
+1.11%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Revolution Medicines(RVMD.US) Officer Sells US$4.56 Million in Common StockMarket Newswire · 2026/11/19
-
Rating change
RBC Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $260Market Newswire · 2026/10/28
-
Rating change
UBS Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $265Market Newswire · 2026/10/23
-
Bernstein Maintains Revolution Medicines(RVMD.US) With Hold Rating, Raises Target Price to $179Market Newswire · 2026/11/20
-
Rating change
J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $289Market Newswire · 2026/11/10
-
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $230Market Newswire · 2026/11/20
-
Rating change
Analysts Offer Insights on Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT) and Revolution Medicines (RVMD)TipRanks · 2026/10/22
-
Rating change
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $222 to $340Market Newswire · 2026/11/6
-
Rating change
H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $350Market Newswire · 2026/11/6
-
Rating change
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $264Market Newswire · 2026/10/26
-
Rating change
TD Cowen Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $250Market Newswire · 2026/10/21
-
Revolution Medicines(RVMD.US) Officer Sells US$6.72 Million in Common StockMarket Newswire · 2026/11/14
-
Rating change
Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $241Market Newswire · 2026/10/19
-
Rating change
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $222 to $321Market Newswire · 2026/11/5
-
H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $350Market Newswire · 2026/11/17
-
Rating change
Morgan Stanley Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $247Market Newswire · 2026/11/13
-
Rating change
J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy RatingMarket Newswire · 2026/10/21
-
Rating change
Morgan Stanley Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $255Market Newswire · 2026/10/23
-
Rating change
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $274Market Newswire · 2026/11/13
-
Rating change
Morgan Stanley Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $272Market Newswire · 2026/11/6
-
Rating change
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $264Market Newswire · 2026/10/9
-
Rating change
Guggenheim Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $275Market Newswire · 2026/10/16
-
Rating change
Needham Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $275Market Newswire · 2026/10/15
-
Rating change
LifeSci Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $315Market Newswire · 2026/10/5
-
Rating change
RBC Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $260Market Newswire · 2026/10/14
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.
Revolution Medicines discussion 0 comments